Breaking News Instant updates and real-time market news.

ACRX

AcelRx

$3.81

-0.065 (-1.68%)

, ATRS

Antares Pharma

$3.25

-0.1 (-2.99%)

08:32
10/02/18
10/02
08:32
10/02/18
08:32

Ladenburg to hold a conference

2018 Healthcare Conference will be held in New York on October 2 with webcasted company presentations to begin at 8:30 am; not all company presentations may be webcasted. Webcast Link

ACRX

AcelRx

$3.81

-0.065 (-1.68%)

ATRS

Antares Pharma

$3.25

-0.1 (-2.99%)

MNOV

MediciNova

$12.85

0.37 (2.96%)

CBIO

Catalyst Biosciences

$10.51

-0.26 (-2.41%)

LPCN

Lipocine

$1.38

-0.015 (-1.08%)

YTEN

Yield10 Bioscience

$1.45

0.03 (2.11%)

ONCY

Oncolytics

$4.02

0.14 (3.61%)

PTN

Palatin

$0.97

-0.02 (-2.02%)

VERU

Veru

$1.32

-0.11 (-7.69%)

MESO

Mesoblast

$8.63

0.47 (5.76%)

NTGN

Neon Therapeutics

$11.52

2.97 (34.74%)

EYEN

Eyenovia

$3.85

-0.15 (-3.75%)

RDHL

RedHill Biopharma

$8.92

0.09 (1.02%)

CYCC

Cyclacel Pharmaceuticals

$1.40

0.02 (1.45%)

DOVA

Dova Pharmaceuticals

$20.70

-0.23 (-1.10%)

LPTX

Leap Therapeutics

$7.94

0.09 (1.15%)

OVID

Ovid Therapeutics

$5.72

0.09 (1.60%)

CLLS

Cellectis

$27.92

-0.34 (-1.20%)

CURE

Curative Health Services Inc

$67.80

1.28 (1.92%)

OPGN

OpGen

$1.96

-0.04 (-2.00%)

TRIL

Trillium Therapeutics

$5.77

-0.18 (-3.03%)

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 03

    Oct

  • 12

    Oct

  • 03

    Nov

  • 13

    Nov

  • 27

    Nov

ACRX AcelRx
$3.81

-0.065 (-1.68%)

08/16/18
LTCO
08/16/18
INITIATION
Target $7
LTCO
Buy
AcelRx initiated with a Buy at Ladenburg
Ladenburg analyst Michael Higgins initiated AcelRx with a Buy and $7 price target.
07/13/18
OPCO
07/13/18
INITIATION
OPCO
Perform
AcelRx initiated with a Perform at Oppenheimer
Oppenheimer analyst Leland Gershell initiated AcelRx with a Perform rating, citing regulatory uncertainty and commercial headwinds. In a note to investors, Gershell says that he "lacks conviction" on Dsuvia and Zalviso's ability to take meaningful share within the large acute pain/injectable opioid treatment market and that he is "cautious" in the near-term on Dsuvia's late-2018 FDA decision in a regulatory and societal atmosphere attuned to opioids' liabilities.
08/16/18
08/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Post Holdings (POST) initiated with an Overweight at Piper Jaffray. 2. Stryker (SYK) initiated with a Buy at BTIG. 3. Aveo Pharmaceuticals (AVEO) initiated with a Buy at H.C. Wainwright. 4. Uxin (UXIN) initiated with a Buy at Goldman Sachs. 5. AcelRx (ACRX) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/12/18
CANT
06/12/18
INITIATION
CANT
Cantor expands Specialty Pharmaceuticals coverage with eight names
Cantor Fitzgerald analyst Brandon Folkes last night rolled out coverage on eight names in the Specialty Pharmaceuticals space. He initiated coverage of AcelRx (ACRX), ANI Pharmaceuticals (ANIP), Biohaven Pharmaceutical (BHVN), Collegium Pharmaceutical (COLL), Emergent BioSolutions (EBS), Eagle Pharmaceuticals (EGRX) and Opiant Pharmaceuticals (OPNT) with Overweight ratings. There is still value to be unlocked in these stocks at current valuations with risk/reward profiles that remain to the upside, Folkes told investors in a research note. His top picks are ANI Pharmaceuticals, Emergent BioSolutions and Collegium Pharmaceutical. The analyst rounded out his coverage with a Neutral rating on Momenta (MNTA), saying the recent share rally puts him on the sidelines "for now."
ATRS Antares Pharma
$3.25

-0.1 (-2.99%)

05/08/18
HCWC
05/08/18
NO CHANGE
Target $4
HCWC
Buy
Antares target raised to $4 on higher Xyosted confidence at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat said that Antares Pharma reported "solid" Q1 results but "most importantly...finally explicitly confirmed a key aspect of the Xyosted filing," specifically that the company already conducted an ambulatory blood pressure monitoring study as part of the supplemental safety study ahead of the NDA submission. That fact, along with Antares' ability to re-submit the NDA just a week after receiving the minutes from the FDA Type-A meeting, increases his confidence in Xyosted approval coming in 2018, Livnat said. He raised his view of Xyosted's probability of success to 70% from 40% and increased his price target to $4 from $3.50 on Antares shares. Livnat keeps a Buy rating on the stock.
10/23/17
RAJA
10/23/17
NO CHANGE
Target $3.4
RAJA
Strong Buy
Antares Pharma maintained as a Strong Buy at Raymond James
Raymond James analyst Elliot Wilbur said the FDA's CRL on Antares Pharma (ATRS) XYOSTED was an unexpected and significant setback, but weakness in shares since the October disclosure effectively prices XYOSTED at zero, and substantially undervalues other development programs, especially ANDA products with Teva (TEVA). Wilbur is not writing-off XYSTED yet and is pushing out an expected launch to 2H19 from early 2018 previously, and is now discounting the probability of success at 50% versus 100% prior to the CRL. The analyst maintains asset values for Antares' non-XYOSTED assets are worth $2.50 per share using a sum-of-the-parts valuation and adjusted his price target to $3.40 from $4.20 on shares. Wilbur maintains a Strong Buy rating on Antares
10/23/17
JANY
10/23/17
NO CHANGE
JANY
Neutral
Antares CRL doesn't raise issues for Amag Pharmaceuticals, says Janney Capital
Janney Capital analyst Ken Trbovich noted that the FDA complete response letter issued to Antares (ATRS) for Xyosted did not pertain to the Quickshot subcutaneous autoinjector, which raises his confidence the FDA will not identify such issues as a short coming of the sNDA for Amag Pharmaceuticals' (AMAG) Makena SQ. However, he keeps a Neutral rating on Amag shares, noting that the primary uncertainty for the sNDA for Makena SQ is the fact that its peak plasma levels is higher than the upper bound the FDA uses to define bioequivalence.
08/17/18
HCWC
08/17/18
NO CHANGE
Target $4.5
HCWC
Buy
H.C. Wainwright ups Antares price target to $4.50 after generic EpiPen approval
After the FDA announced the "long-awaited" approval of Antares Pharma (ATRS) and partner Teva's (TEVA) generic EpiPen, H.C. Wainwright analyst Oren Livnat said his estimates include nearly $40M in peak EpiPen revenue to Antares from the "biggest partnered pipeline opportunity" the company has modeled by his and consensus estimates. Livnat, who said he is not aware of any other substitutable EpiPen generics on the way, views the product as a sustainable contributor and raised his price target on Antares shares to $4.50 from $4.00 following the news. Livnat, who assumes Teva launches quickly after final label packaging, but believes that Teva "unfortunately" will miss the big EpiPen back-to-school prescribing season, keeps a Buy rating on Antares shares.
MNOV MediciNova
$12.85

0.37 (2.96%)

03/28/18
RILY
03/28/18
INITIATION
Target $22
RILY
Buy
MediciNova initiated with a Buy at B. Riley FBR
B. Riley FBR analyst David Buck started MediciNova with a Buy rating and $22 price target.
CBIO Catalyst Biosciences
$10.51

-0.26 (-2.41%)

02/09/18
CHDN
02/09/18
NO CHANGE
Target $75
CHDN
Buy
Catalyst Biosciences price target raised to $75 from $10 at Chardan
02/09/18
02/09/18
NO CHANGE
Target $75

Buy
Catalyst price target raised to $75 after hemophilia B data at Chardan
As previously reported, Chardan raised its price target on Catalyst Biosciences to $75 from $10, with analyst Gbola Amusa arguing that data presented at the European Association for Haemophilia and Allied Disorders showed the potential of CB 2679d to become "not just the first subcutaneously-delivered factor IX product in hemophilia B, but also a better overall product." Credible comparisons to Catalyst in the hemophilia B market trade at a minimum market cap of $500M-$600M, said the analyst, who has a Buy rating on the shares.
06/21/18
RILY
06/21/18
DOWNGRADE
Target $12.5
RILY
Neutral
Catalyst Biosciences downgraded to Neutral from Buy at B. Riley FBR
B. Riley FBR analyst George Zavoico downgraded Catalyst Biosciences to Neutral and cut his price target for the shares to $12.50 from $44.
06/21/18
06/21/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Nike (NKE) downgraded to Neutral from Buy at UBS with analyst Jay Sole saying Nike's "comeback after two relatively down years continues." 2. Infinera (INFN) downgraded to Neutral from Buy at Goldman Sachs with analyst Rod Hall assumed coverage from Doug Clark and downgrading the stock to Neutral from Buy while saying the company's success is dependent on the new products, while its "key higher TAM products are yet to fully hit the market." 3. AMC Networks (AMCX) downgraded to Underperform from Market Perform at Bernstein with analyst Todd Juenger saying he thinks it is unlikely the company will be acquired at a premium. 4. Catalyst Biosciences (CBIO) downgraded to Neutral from Buy at B. Riley FBR. 5. Noble Corp. (NE) downgraded to Hold from Buy at Jefferies with analyst Eduardo Royes saying the stock is up 18% year-to-date versus its four major peers rising only 2%. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LPCN Lipocine
$1.38

-0.015 (-1.08%)

03/29/18
GHSC
03/29/18
INITIATION
Target $10
GHSC
Buy
Lipocine initiated with a Buy at Seaport Global
Seaport Global analyst Corey Davis initiated Lipocine with a Buy and $10 price target. The analyst believes investors have given up on approval for Tlando given the complete response letter in 2016, the negative FDA AdCom, and current valuation. Davis does not expect FDA approval on the final FDA May 8 PDUFA, but thinks the agency may ask for ambulatory blood pressure study and study comparing "serum" testosterone to "plasma" testosterone in patients before and after dosing. If so, shares should react favorably and if the studies are positive, shares could react significantly.
02/27/18
EAMC
02/27/18
UPGRADE
EAMC
Buy
Lipocine upgraded to Buy from Hold at Empire
Empire analyst Cathy Reese upgraded Lipocine to Buy with a $21 price target, shares currently trade at $1.31, saying there is a high probability Tlando will gain approval, whether its on the May 8 PDUFA or once the once the blood pressure and collection test tube clinical data is reviewed sometime in 2018.
01/12/18
HCWC
01/12/18
NO CHANGE
Target $3
HCWC
Buy
Lipocine price target lowered to $3 from $10 at H.C. Wainwright
H.C. Wainwright analyst Oren Livnat lowered his price target for Lipocine to $3 saying the company is a "show me" story following the negative Tlando FDA panel vote. The analyst keeps a Buy rating on the shares.
01/11/18
LTCO
01/11/18
NO CHANGE
Target $11
LTCO
Buy
Lipocine price target lowered to $11 from $15 at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan cut his price target for Lipocine to $11 after an FDA committee voted 13 to 6 that the risk/benefit profile of Tlando is not currently supportive of approval for the treatment of hypogonadism. The analyst believes Tlando continues to represent an approvable product and that the blood pressure question can be addressed via a relatively a "relatively straightforward" study. Kaplan cites the likelihood of a complete response letter from the FDA for his target reduction but keeps a Buy rating on Lipocine shares.
YTEN Yield10 Bioscience
$1.45

0.03 (2.11%)

07/12/18
MAXM
07/12/18
INITIATION
MAXM
Buy
Yield10 Bioscience initiated with a Buy at Maxim
ONCY Oncolytics
$4.02

0.14 (3.61%)

10/01/18
LTCO
10/01/18
INITIATION
Target $22
LTCO
Buy
Oncolytics initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Wangzhi Li started Oncolytics Biotech with a Buy rating and $22 price target. The analyst believes Oncolytics is "significantly under-recognized and undervalued, and presents an attractive investment opportunity." The company's lead program Pelareorep is a RNA reovirus oncolytic virus that has been safely dosed in greater than 1,100 patients across a variety of cancers, Li points out.
PTN Palatin
$0.97

-0.02 (-2.02%)

04/06/18
HCWC
04/06/18
INITIATION
Target $5
HCWC
Buy
Palatin initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis started Palatin Technologies with a Buy rating and $5 price target. The analyst views the company's lead asset bremelanotide, which is in development for hypoactive sexual desire disorder in women, as "significantly derisked." He believes the drug's "checked boxes" and projected catalysts are not reflected in the current share price.
06/27/18
LTCO
06/27/18
INITIATION
Target $3
LTCO
Buy
Palatin initiated with a Buy at Ladenburg
Ladenburg analyst Michael Higgins initiated Palatin with a Buy rating and $3 price target.
06/14/18
HCWC
06/14/18
NO CHANGE
HCWC
Buy
Palatin weakness 'undeserved' following Addyi relaunch, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis attributes recent weakness in shares of Palatin (PTN) to the relaunch of Addyi by Sprout, and its first-to-market status, following reacquisition of the drug from Valeant (VRX). However, he sees the weakness as undeserved, as he continues to believe that Addyi is an inferior drug with a "sketchy history," Pantginis tells investors. Addyi's "one singular advantage," education and visibility for hypoactive sexual desire disorder, should help the market for Palatin's bremelanotide, which has a "potentially market leading profile," said the analyst, who keeps a Buy rating on Palatin shares.
VERU Veru
$1.32

-0.11 (-7.69%)

08/28/18
HCWC
08/28/18
NO CHANGE
Target $5
HCWC
Buy
Veru female condom order could be worth $15M, says H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju believes Veru's 75% award of a South Africa female condom tender, which is in line with management's prior expectation, could be worth $15M and be delivered by the end of calendar year 2018. The tender award should provide "solid" cash flows to the company to help the continued development of its oncology and urology drug candidates, Selvaraju tells investors in a research note. He notes Veru may also receive part of the 35M unit tender from Brazil in the coming quarters. The analyst reiterates a Buy rating on the shares with a $5 price target.
07/03/18
07/03/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Veru Inc. (VERU) initiated with a Buy at Maxim. 2. ViewRay (VRAY) initiated with a Buy at Jefferies. 3. MeiraGTx (MGTX) initiated with an Overweight at Barclays. 4. Zafgen (ZFGN) initiated with an Overweight at Piper Jaffray. 5. Eloxx Pharmaceuticals (ELOX) initiated with a Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/03/18
MAXM
07/03/18
INITIATION
Target $10
MAXM
Buy
Veru Inc. initiated with a Buy at Maxim
Maxim analyst Jason McCarthy initiated Veru Inc. with a Buy rating and $10.00 price target.
04/06/18
04/06/18
INITIATION
Target $10

Veru initiated with a Buy at Brookline Capital
Brookline Capital initiated Veru with a Buy and $10 price target.
MESO Mesoblast
$8.63

0.47 (5.76%)

03/22/18
FBCO
03/22/18
DOWNGRADE
FBCO
Underperform
Mesoblast downgraded to Underperform from Neutral at Credit Suisse
03/22/18
03/22/18
DOWNGRADE
Target $6

Underperform
Mesoblast downgraded to Underperform at Credit Suisse
As previously reported, Credit Suisse analyst Alethia Young downgraded Mesoblast to Underperform from Neutral and lowered her price target on the shares to $6 from $11 due to slower launch timelines. The analyst is cautious into the upcoming LVAD advanced heart failure study, 12-month data in Q3.
06/07/18
HCWC
06/07/18
INITIATION
Target $17
HCWC
Buy
Mesoblast initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert started Mesoblast with a Buy rating and $17 price target. The analyst sees Mesoblast as having the strongest pipeline in the regenerative medicine space.
07/18/18
MAXM
07/18/18
NO CHANGE
Target $16
MAXM
Buy
Mesoblast price target raised to $16 at Maxim on Tasly deal in China
Maxim analyst Jason McCarthy raised his price target on Mesoblast to $16 from $14 and kept his Buy rating. The analyst cites the company's announced partnership with Tasly Pharma in China for development of MPC-150-IM in chronic heart failure and MPC-25-IC in acute myocardial infarction, adding that market into his model. McCarthy further points to Mesoblast's improved balance sheet as a result of this "great" partnership.
NTGN Neon Therapeutics
$11.52

2.97 (34.74%)

07/23/18
BOFA
07/23/18
INITIATION
Target $18
BOFA
Buy
Neon Therapeutics initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Ying Huang initiated Neon Therapeutics with a Buy and $18 price target. Huang sees a large market opportunity for Neon's personalized and "off-the-shelf" anti-cancer therapies, but notes theses therapies are in their infancy.
07/23/18
MSCO
07/23/18
INITIATION
Target $23
MSCO
Overweight
Neon Therapeutics initiated with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison initiated Neon Therapeutics with an Overweight rating and $23 price target, as he views neoantigens as a relevant target that could improve the efficacy of current checkpoint inhibitors and believes initial data demonstrates an impact on the tumor. He sees 2019 as a pivotal year for Neon and expects followup from the initial data to drive outperformance, Harrison tells investors.
07/23/18
OPCO
07/23/18
INITIATION
Target $20
OPCO
Outperform
Neon Therapeutics initiated with an Outperform at Oppenheimer
Oppenheimer analyst Leah Rush Cann started Neon Therapeutics with an Outperform rating and $20 price target. The analyst estimates that Neon Therapeutics will first have product revenue in 2024 resulting in total revenue that year of $676.8M, potentially growing to $3.67B in 2025, if NEO-PV-01 is successful in currently planned indications.
10/01/18
LTCO
10/01/18
INITIATION
Target $20
LTCO
Buy
Neon Therapeutics initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter started Neon Therapeutics with a Buy rating and $20 price target. The analyst believes NEO-PV-01 "enjoys a powerful first mover advantage" in neoantigen therapies for improving both the depth and breadth of response of checkpoint inhibitors.
EYEN Eyenovia
$3.85

-0.15 (-3.75%)

02/20/18
ROTH
02/20/18
INITIATION
Target $20
ROTH
Buy
Eyenovia initiated with a Buy at Roth Capital
Roth Capital analyst Scott Henry started Eyenovia with a Buy rating and a $20 price target, citing a favorable risk/reward profile for the company's emerging pipeline, particularly MicroProst for the treatment of chronic angle closure glaucoma.
RDHL RedHill Biopharma
$8.92

0.09 (1.02%)

01/26/18
01/26/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Williams Scotsman (WSC) initiated with an Outperform at Oppenheimer. 2. RedHill Biopharma (RDHL) initiated with a Buy at Nomura Instinet. 3. BioDelivery Sciences (BDSI) initiated with a Buy at Seaport Global. 4. NuStar GP Holdings (NSH) initiated with a Buy at B. Riley FBR. 5. Atara Biotherapeutics (ATRA) initiated with an Outperform at Cowen. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/25/18
LTCO
06/25/18
INITIATION
Target $20
LTCO
Buy
RedHill Biopharma initiated with a Buy at Ladenburg
Ladenburg analyst Matthew Kaplan initiated RedHill Biopharma with a Buy rating and $20 price target.
01/26/18
NOMU
01/26/18
INITIATION
Target $18
NOMU
Buy
RedHill Biopharma initiated with a Buy at Nomura Instinet
Nomura Instinet analyst Chris Marai started RedHill Biopharma with a Buy rating and $18 price target. The analyst views the risk/reward as attractive ahead of catalysts in 2018.
06/25/18
06/25/18
INITIATION
Target $20

Buy
RedHill Biopharma initiated with a Buy and $20 price target at Ladenburg
As previously reported, Ladenburg analyst Matthew Kaplan initiated RedHill Biopharma with a Buy rating and $20 price target, citing his focus on the company's portfolio of late-stage compounds. RHB-104, which is being developed for the treatment of Crohn's disease, could generate over $375M in U.S. revenues in 2030 while RHB-105 for the treatment of Helicobacter pylori infection could generate over $350M in peak U.S. revenues for this indication in 2027, Kaplan predicts.
CYCC Cyclacel Pharmaceuticals
$1.40

0.02 (1.45%)

09/07/18
LTCO
09/07/18
INITIATION
Target $6.25
LTCO
Buy
Cyclacel Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Kevin DeGeeter started Cyclacel Pharmaceuticals with a Buy rating and $6.25 price target. The analyst believes CYC065 has shown promise in Mcl-1 regulation.
09/05/18
ROTH
09/05/18
INITIATION
Target $8
ROTH
Buy
Cyclacel Pharmaceuticals initiated with a Buy at Roth Capital
Roth Capital analyst Jotin Marango started Cyclacel Pharmaceuticals with a Buy rating and $8 price target. The analyst believes that Cyclacel, its clinical CDK inhibitor CYC065, and its indirect target MCL-1 should all go into the watchlist of anyone interested in CLL.
DOVA Dova Pharmaceuticals
$20.70

-0.23 (-1.10%)

07/09/18
LEER
07/09/18
DOWNGRADE
LEER
Market Perform
Dova Pharmaceuticals downgraded to Market Perform from Outperform at Leerink
04/26/18
LTCO
04/26/18
INITIATION
Target $65
LTCO
Buy
Dova Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg Thalmann analyst Matthew Kaplan started Dova Pharmaceuticals with a Buy rating and $65 price target.
09/17/18
JEFF
09/17/18
NO CHANGE
Target $40
JEFF
Buy
Physician poll positive for Dova Pharmaceuticals' Doptelet, says Jefferies
Jefferies analyst Eun Yang says her physician poll results on Dova Pharmaceuticals' Doptelet are "highly encouraging." The analyst sees high awareness and more favorable rates upon use of Doptelet versus current standard of care, or platelet transfusion, three months into launch as positives. Further, Doptelet preference among the polled doctors surpasses competitor Mulpleta despite a higher list pricing, Yang tells investors in a research note. She keeps a Buy rating on Dova with a $40 price target.
08/29/18
RAJA
08/29/18
INITIATION
Target $44
RAJA
Outperform
Dova Pharmaceuticals initiated with an Outperform at Raymond James
Raymond James analyst Laura Chico initiated Dova Pharmaceuticals with an Outperform and $44 price target. Chico's physician survey indicates suggest a need for novel treatments like Dova's Droptelet and said investor expectations are modest, providing a favorable setup for shares.
LPTX Leap Therapeutics
$7.94

0.09 (1.15%)

04/12/18
04/12/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Mallinckrodt (MNK) initiated with a Hold at SunTrust. 2. Hershey (HSY) initiated with a Neutral at Piper Jaffray. 3. Autoliv (ALV) initiated with a Hold at Cross Research. 4. Leap Therapeutics (LPTX) initiated with a Buy at H.C. Wainwright. 5. Monolithic Power (MPWR) initiated with a Strong Buy at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
04/12/18
HCWC
04/12/18
INITIATION
Target $12.5
HCWC
Buy
Leap Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started Leap Therapeutics with a Buy rating and $12.50 price target. The company has two novel products targeting the tumor microenvironment, Ramakanth tells investors in a research note. He believes Leap's products could significantly improve the typical 15%-20% response rates seen with current immunotherapies when used in combination.
OVID Ovid Therapeutics
$5.72

0.09 (1.60%)

04/20/18
LTCO
04/20/18
INITIATION
Target $27
LTCO
Buy
Ovid Therapeutics initiated with a Buy at Ladenburg
Ladenburg analyst Michael Higgins initiated Ovid Therapeutics with a Buy and $27 price target.
08/06/18
PIPR
08/06/18
NO CHANGE
Target $20
PIPR
Overweight
Ovid Therapeutics shares should recover from here, says Piper Jaffray
Piper Jaffray analyst Tyler Van Buren attributes Ovid Therapeutics' selloff to the lack of statistical significance on the domain-based endpoints in the Phase 2 STARS trial, but he believes the shares will recover from these levels as appreciation for the just-reported data grows and as the report of OV935 proof of concept dEE data near year-end approaches. The analyst, who thinks the dEE data has "exciting potential," keeps an Overweight rating and $20 price target on Ovid shares, which are down 35% to $6.20 in afternoon trading.
08/10/18
PIPR
08/10/18
NO CHANGE
Target $20
PIPR
Overweight
Piper sees value coming back into Ovid shares after pullback
Shares of Ovid Therapeutics have pulled back following the recent Angelman's data release, but investors underappreciate the exploratory nature of what was the first study of its kind, Piper Jaffray analyst Tyler Van Buren tells investors in a research note. Further, he believes the FDA will give flexibility in designing a registrational program for OV101 given the lack of treatments option and the significant unmet needs that exists for these patients. The analyst maintains an Overweight rating on Ovid with a $20 price target, believing share value will accrue as investors get a greater appreciation for the OV101 program and opportunity.
05/18/18
PIPR
05/18/18
INITIATION
Target $20
PIPR
Overweight
Ovid Therapeutics assumed with an Overweight at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren assumed coverage of Ovid Therapeutics with an Overweight rating and $20 price target. The company is enrolling genetically-defined orphan populations with preclinical models that have demonstrated encouraging results, Van Buren tells investors in a research note.
CLLS Cellectis
$27.92

-0.34 (-1.20%)

07/16/18
LEHM
07/16/18
INITIATION
Target $50
LEHM
Overweight
Barclays starts Cellectis with Overweight rating, $50 price target
Barclays analyst Gena Wang initiated coverage of Cellectis S.A. with an Overweight rating and $50 price target. Following "impressive data" and several approvals of personalized autologous CAR-T cell therapies in various blood cancers, universal off-the-shelf allogeneic CAR-T would be future therapeutic approach with improved timeline, costs and homogeneity, Wang tells investors in a research note. As a leader in allo-CART with its proprietary Talen gene editing technology, Cellectis is the only company with clinical experience, on two programs, the analyst adds. She believes the company has a "strong" pipeline of allogeneic CAR-Ts targeting advanced blood cancers.
04/24/18
JEFF
04/24/18
NO CHANGE
Target $27
JEFF
Buy
Epizyme shares will bounce back, says Jefferies
Jefferies analyst Michael Yee says that while the partial clinical hold is a bad headline, shares of Epizyme (EPZM) will bounce back like Cellectis (CLLS), Juno and others did when they modified the protocol and trial brochures to get back up and running. After speaking to management, Yee thinks Epizyme's partial clinical hold will be lifted in a few months. Until then, however, the shares could be in the penalty box, the analyst tells investors in a research note. He keeps a Buy rating on Epizyme with a $27 price target.
07/16/18
LEHM
07/16/18
INITIATION
Target $50
LEHM
Overweight
Cellectis initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Cellectis with an Overweight rating and $50 price target.
06/12/18
OPCO
06/12/18
NO CHANGE
Target $44
OPCO
Outperform
Cellectis price target raised to $44 from $40 at Oppenheimer
Oppenheimer analyst Hartaj Singh raised his price target for Cellectis to $44 from $40 after the company announced that the FDA approved its IND filing for UCART22 following a 30-day review period. The analyst reiterates an Outperform rating on the shares.
CURE Curative Health Services Inc
$67.80

1.28 (1.92%)

OPGN OpGen
$1.96

-0.04 (-2.00%)

TRIL Trillium Therapeutics
$5.77

-0.18 (-3.03%)

04/13/18
LEER
04/13/18
INITIATION
Target $7
LEER
Market Perform
Trillium Therapeutics resumed with a Market Perform at Leerink
Leerink analyst Jonathan Chan resumed coverage of Trillium Therapeutics with a Market Perform rating and $7 price target. The analyst views the early-stage CD47 space as "competitive with an increasing number of programs in development." he finds it difficult to pick a winner at this time.
12/14/17
HCWC
12/14/17
NO CHANGE
Target $10
HCWC
Buy
Trillium price target raised to $10 from $7 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised his price target for Trillium Therapeutics to $10 saying the company presented "impressive" first results from the Phase 1 study of intratumoral TTI-621 for the treatment of relapsed or refractory mycosis fungoides. The analyst believes TTI-621 could become a "highly efficacious treatment." He reiterates a Buy rating on the shares.

TODAY'S FREE FLY STORIES

SLM

Sallie Mae

$10.58

(0.00%)

17:23
10/22/18
10/22
17:23
10/22/18
17:23
Hot Stocks
Sallie Mae reports Q3 net interest margin up 15bps at 6.00% »

Q3 Private education loan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

SLM

Sallie Mae

$10.58

(0.00%)

17:22
10/22/18
10/22
17:22
10/22/18
17:22
Earnings
Sallie Mae raises FY18 core EPS view to $1.02-$1.03 from 99c-$1.01 »

Consensus$1.02. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

SLM

Sallie Mae

$10.58

(0.00%)

17:19
10/22/18
10/22
17:19
10/22/18
17:19
Earnings
Sallie Mae reports Q3 adjusted EPS 23c, consensus 24c »

Reports Q3 NII $356.6M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Nov

BA

Boeing

$355.98

-0.3 (-0.08%)

17:17
10/22/18
10/22
17:17
10/22/18
17:17
Hot Stocks
Correction: Boeing maintains quarterly dividend of $1.71 »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

JOE

Saint Joe Co.

$15.08

-0.14 (-0.92%)

, MAR

Marriott

$111.49

-0.58 (-0.52%)

17:15
10/22/18
10/22
17:15
10/22/18
17:15
Hot Stocks
St. Joe Company, InterMountain break ground on New Towneplace Suites Hotel »

The St. Joe Company (JOE)…

JOE

Saint Joe Co.

$15.08

-0.14 (-0.92%)

MAR

Marriott

$111.49

-0.58 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

RNST

Renasant

$35.44

-1.1 (-3.01%)

17:11
10/22/18
10/22
17:11
10/22/18
17:11
Earnings
Renasant reports Q3 adjusted EPS 61c, consensus 77c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 06

    Dec

IAG

IAMGold

$3.84

-0.13 (-3.27%)

17:09
10/22/18
10/22
17:09
10/22/18
17:09
Hot Stocks
IAMGold announces positive results from a feasibility study for Senegal project »

IAMGOLD announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

HWBK

Hawthorn Bancshares

$23.20

-0.27 (-1.15%)

17:09
10/22/18
10/22
17:09
10/22/18
17:09
Hot Stocks
Breaking Hot Stocks news story on Hawthorn Bancshares »

Endeavour Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNBC

Green Bancorp

$19.34

-0.7 (-3.49%)

17:07
10/22/18
10/22
17:07
10/22/18
17:07
Earnings
Green Bancorp reports Q3 EPS 49c, consensus 47c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

VBTX

Veritex

$24.43

-1.07 (-4.20%)

17:06
10/22/18
10/22
17:06
10/22/18
17:06
Earnings
Veritex reports Q3 core EPS 34c, consensus 46c »

Reports Q3 tangible book…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

IBTX

Independent Bank

$56.47

-3.06 (-5.14%)

17:04
10/22/18
10/22
17:04
10/22/18
17:04
Earnings
Independent Bank reports Q3 EPS $1.20, consensus $1.20 »

Net interest income was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Nov

BRO

Brown & Brown

$29.12

0.27 (0.94%)

17:03
10/22/18
10/22
17:03
10/22/18
17:03
Hot Stocks
Breaking Hot Stocks news story on Brown & Brown »

Brown & Brown reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 02

    Nov

  • 14

    Nov

SFNC

Simmons First National

$25.62

-0.78 (-2.95%)

17:03
10/22/18
10/22
17:03
10/22/18
17:03
Hot Stocks
Breaking Hot Stocks news story on Simmons First National »

Simmons First National…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Nov

CR

Crane

$87.33

-0.28 (-0.32%)

17:03
10/22/18
10/22
17:03
10/22/18
17:03
Earnings
Crane raises FY18 EPS ex-items view to $5.80-$5.90 from $5.60-$5.80 »

Consensus $5.75. Raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Dec

  • 06

    Dec

GNBC

Green Bancorp

$19.34

-0.7 (-3.49%)

17:02
10/22/18
10/22
17:02
10/22/18
17:02
Earnings
Green Bancorp reports Q3 non-GAAP EPS 49c, consensus 47c »

Reports Q3 provision for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

SFNC

Simmons First National

$25.62

-0.78 (-2.95%)

17:02
10/22/18
10/22
17:02
10/22/18
17:02
Earnings
Simmons First National reports Q3 core EPS 61c, consensus 58c »

Reports Q3 net interest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 26

    Nov

CR

Crane

$87.33

-0.28 (-0.32%)

17:02
10/22/18
10/22
17:02
10/22/18
17:02
Earnings
Crane reports Q3 EPS ex-items $1.62, consensus $1.46 »

Reports Q3 revenue $856M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Dec

  • 06

    Dec

BRO

Brown & Brown

$29.12

0.27 (0.94%)

17:01
10/22/18
10/22
17:01
10/22/18
17:01
Earnings
Brown & Brown reports Q3 adjusted EPS 38c, consensus 34c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 02

    Nov

  • 14

    Nov

NBTB

NBT Bancorp

$36.29

-0.57 (-1.55%)

16:54
10/22/18
10/22
16:54
10/22/18
16:54
Hot Stocks
NBT Bancorp raises quarterly dividend to 26c from 25c per share »

The dividend will be paid…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBTB

NBT Bancorp

$36.29

-0.57 (-1.55%)

16:54
10/22/18
10/22
16:54
10/22/18
16:54
Earnings
NBT Bancorp reports Q3 adjusted EPS 68c, consensus 65c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PERY

Perry Ellis

$27.50

(0.00%)

16:51
10/22/18
10/22
16:51
10/22/18
16:51
Hot Stocks
Perry Ellis announces completion of its acquisition in $437M transaction »

Perry Ellis International…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

FBK

FB Financial

$33.54

-1.36 (-3.90%)

16:51
10/22/18
10/22
16:51
10/22/18
16:51
Earnings
FB Financial reports Q3 adjusted EPS 68c, consensus 72c »

President and Chief…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 05

    Dec

  • 06

    Dec

FBK

FB Financial

$33.54

-1.36 (-3.90%)

16:49
10/22/18
10/22
16:49
10/22/18
16:49
Hot Stocks
FB Financial authorizes $50M common stock repurchase program »

FB Financial's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 05

    Dec

  • 06

    Dec

FBK

FB Financial

$33.54

-1.36 (-3.90%)

16:48
10/22/18
10/22
16:48
10/22/18
16:48
Hot Stocks
FB Financial increases quarterly dividend 33% »

FB Financial Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 05

    Nov

  • 13

    Nov

  • 14

    Nov

  • 15

    Nov

  • 05

    Dec

  • 06

    Dec

SSB

South State

$73.05

-1.975 (-2.63%)

16:48
10/22/18
10/22
16:48
10/22/18
16:48
Earnings
South State reports Q3 adjusted EPS $1.33, consensus $1.40 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.